Table 2.
Reductions in HbAlc by Treatment Group at Months 6 and 12
| Time Point | OT | Diabetes Education | RR (95% CI) | P Value |
|---|---|---|---|---|
| Month 6 | ||||
| Raw rate, No./total (%)a | 25/41 (61.0) | 22/46 (47.8) | ||
| Model-estimated rate (95% CI)b | 0.58 (0.45 to 0.75) | 0.48 (0.36 to 0.64) | 1.21 (0.84 to 1.75) | .31 |
| HbAlc ≥ 9.0% (n = 43): model-estimated rate (95% CI)b | 0.74 (0.57 to 0.96) | 0.60 (0.43 to 0.84) | 1.24 (0.83 to 1.87) | .29 |
| HbAlc < 9.0% (n = 44): model-estimated rate (95% CI)b | 0.46 (0.28 to 0.74) | 0.40 (0.24 to 0.66) | 1.15(0.58 to 2.31) | .68 |
| Mean change in HbAlc from baseline to 6 mo (95% CI)b | −0.78 (−1.23 to −0.33) | .0008 | ||
| Mean change in HbAlc from baseline to 6 mo (95% CI)b | −0.44 (−0.87 to −0.004) | .0480 | ||
| Treatment group difference in mean change in HbAlc, mean (95% CI) (OT − diabetes education) | −0.34 (−0.97 to 0.28) | .2785 | ||
| Month 12 | ||||
| Raw rate, No./total (%)a | 21/39 (53.9) | 24/49 (49.0) | ||
| Model-estimated rate (95% CI)b | 0.50 (0.37 to 0.68) | 0.48 (0.36 to 0.64) | 1.05 (0.70 to 1.57) | .81 |
| HbAlc ≥ 9.0% (n = 44): model-estimated rate (95% CI)b | 0.66 (0.48 to 0.92) | 0.57 (0.41 to 0.80) | 1.16 (0.74 to 1.83) | .51 |
| HbAlc < 9.0% (n = 44): model-estimated rate (95% CI)b | 0.36 (0.20 to 0.65) | 0.41 (0.25 to 0.67) | 0.89 (0.41 to 1.91) | .75 |
| Mean change in HbAlc from baseline to 12 mo (95% CI)b | −0.91 (−1.45 to −0.37) | .0011 | ||
| Mean change in HbA1c from baseline to 12 mo (95% CI)b | −0.54 (−1.04 to −0.036) | .0358 | ||
| Treatment group difference in mean change in HbAlc, mean (95% CI) (OT − diabetes education) | −0.37 (−1.11 to 0.37) | .3273 | ||
Abbreviations: CI, confidence interval; HbAlc, hemoglobin A1c; OT, occupational therapy; RR, relative risk.
a
Decrease in HbAlc by 0.5%.
b
Adjusted for baseline HbAlc, age, and run-in adherence rate.